Food-as-Medicine Program Cuts Blood Pressure by 13 Points in High-Risk Adults
A pilot trial found tailored DASH coaching plus produce prescriptions slashed systolic BP by 13 mmHg in adherent adults with uncontrolled hypertension.
Summary
A small randomized trial called THRIVE tested whether pairing weekly produce prescriptions with personalized DASH diet coaching could improve blood pressure in Black and Hispanic adults living in food deserts. While the intervention didn't significantly boost overall diet quality scores, participants who closely followed the DASH guidelines saw their systolic blood pressure drop by 13.3 mmHg over 24 weeks — compared to a 2 mmHg rise in the control group. The program included $35 weekly produce vouchers, optional home delivery, dietitian coaching, and text-based support. Results were presented at the National Kidney Foundation's Spring Clinical Meeting and suggest that structured nutritional support, especially for underserved populations, may offer meaningful cardiovascular protection.
Detailed Summary
Hypertension affects roughly half of American adults and is the leading modifiable risk factor for heart disease and chronic kidney disease. It disproportionately burdens Black adults, who face a 59% prevalence rate alongside higher rates of food insecurity and limited access to culturally appropriate care. A new pilot trial suggests that combining produce access with personalized dietary coaching could meaningfully reduce blood pressure in this population.
The THRIVE trial enrolled 80 adults — predominantly Black and Hispanic — living in food deserts across Maryland. Participants had uncontrolled hypertension, with most meeting criteria for stage 1 or stage 2 high blood pressure. The intervention group received weekly $35 produce prescriptions with optional home delivery, tailored DASH diet coaching from registered dietitians, curated recipes, and adaptive two-way text message support. The control group received bags of free produce and social resource links but no personalized coaching.
The primary endpoint — improvement in DASH diet quality scores — did not reach statistical significance, with only a 0.5-point difference between groups at 24 weeks. However, among participants who demonstrated high adherence to DASH principles, systolic blood pressure fell by 13.3 mmHg in the intervention group versus a 2 mmHg increase in controls, a statistically significant difference.
These findings align with a growing body of evidence supporting food-as-medicine approaches in cardiovascular prevention. Experts like Dariush Mozaffarian of Tufts University have argued that poor nutrition is the top driver of death and disability in the U.S., outpacing tobacco and physical inactivity combined. The DASH diet, long recognized for its heart-health benefits, has also been linked to lower risks of cognitive decline and mortality.
Key caveats include the trial's small sample size of 80 participants, its pilot nature, and the fact that blood pressure benefits were observed only in a subset of highly adherent participants — not the full intervention group. Whether these gains are sustained after the program ends remains an open question, as a similar 2025 trial found blood pressure rebounded once grocery deliveries stopped.
Key Findings
- Highly adherent participants saw systolic BP drop 13.3 mmHg versus a 2 mmHg rise in controls over 24 weeks.
- The DASH coaching plus produce prescription program did not significantly improve overall diet quality scores.
- Hypertension prevalence in Black adults reaches 59%, compounded by food insecurity and care access gaps.
- The THRIVE program combined $35 weekly produce vouchers, dietitian coaching, recipes, and text-based support.
- A prior similar trial showed BP gains reversed after the food delivery intervention ended, raising sustainability concerns.
Methodology
This is a meeting coverage news report from MedPage Today summarizing findings from the THRIVE pilot randomized controlled trial presented at the National Kidney Foundation's Spring Clinical Meeting 2026. The trial had a small sample of 80 participants; results are preliminary and not yet published in a peer-reviewed journal, which limits full assessment of methodology and data quality.
Study Limitations
The trial enrolled only 80 participants and is explicitly a pilot study, limiting statistical power and generalizability. Blood pressure benefits appeared only in a high-adherence subgroup, not the full intervention arm, suggesting findings may not apply broadly. Full peer-reviewed publication has not yet occurred, so methodology, randomization quality, and confounders cannot be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.